Unit of Otorhinolaryngology-Head and Neck Surgery, ASST Spedali Civili, Brescia, Italy.
Department of Surgical and Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Laryngoscope. 2022 Jan;132(1):135-141. doi: 10.1002/lary.29738. Epub 2021 Jul 7.
OBJECTIVES/HYPOTHESIS: Laryngeal squamous cell carcinoma (LSCC) has a non-negligible incidence in elderly patients. However, there is still no clear indication on the ideal treatment for early-intermediate glottic LSCC in this specific age group. Both surgical and nonsurgical approaches may be burdened by complications and sequelae that negatively impact patient's health. In this setting, carbon dioxide transoral laser microsurgery (CO TOLMS) is a promising minimally invasive treatment option.
Retrospective case series in a single tertiary academic institution.
Patients who underwent CO TOLMS for Tis-T3 glottic LSCC from 1997 to 2017 were reviewed. Demographic, clinical, and tumor characteristics, as well as postoperative complications were recorded. Overall (OS), disease-specific (DSS), recurrence-free (RFS), laryngo-esophageal dysfunction free survivals (LEDFS), and organ preservation (OP) were calculated.
A total of 134 patients (mean age, 80 ± 4 years; median, 79; range, 75-93) were included in the study. Seven lesions were classified as pTis, 65 as pT1a, 22 as pT1b, 35 as pT2, and 5 as pT3. No treatment-related death was observed. Twenty-eight (20.9%) patients reported 10 surgical and 19 medical complications. Five-year OS, DSS, RFS, LEDFS, and OP were 68.9%, 95.4%, 79.5%, 66%, and 92.5%, respectively. Age and comorbidities were associated with OS and LEDFS. Advanced T categories were negatively correlated with OS, DSS, RFS, LEDFS, and OP. Age and comorbidities were not significant risk factors for complications.
CO TOLMS can be considered a valuable therapeutic approach for selected Tis-T3 glottic LSCC even in the elderly given its favorable oncologic outcomes and minimal aggressiveness.
4 Laryngoscope, 132:135-141, 2022.
目的/假设:喉鳞状细胞癌(LSCC)在老年患者中发病率不容忽视。然而,对于这一年龄组的早期-中期声门 LSCC,目前仍没有明确的理想治疗方法。手术和非手术方法都可能会因并发症和后遗症而带来负担,从而对患者的健康产生负面影响。在这种情况下,二氧化碳经口激光微创手术(CO TOLMS)是一种很有前途的微创治疗选择。
单中心回顾性病例系列研究。
回顾性分析 1997 年至 2017 年间在一家三级学术机构接受 CO TOLMS 治疗的Tis-T3 声门 LSCC 患者。记录患者的人口统计学、临床和肿瘤特征,以及术后并发症。计算总生存率(OS)、疾病特异性生存率(DSS)、无复发生存率(RFS)、喉食管功能无失败生存率(LEDFS)和器官保留率(OP)。
共纳入 134 例患者(平均年龄 80±4 岁,中位数 79 岁,范围 75-93 岁)。7 例为Tis,65 例为 T1a,22 例为 T1b,35 例为 T2,5 例为 T3。无治疗相关死亡。28 例(20.9%)患者报告了 10 例手术和 19 例内科并发症。5 年 OS、DSS、RFS、LEDFS 和 OP 分别为 68.9%、95.4%、79.5%、66%和 92.5%。年龄和合并症与 OS 和 LEDFS 相关。高级 T 分期与 OS、DSS、RFS、LEDFS 和 OP 呈负相关。年龄和合并症不是并发症的显著危险因素。
CO TOLMS 可被视为治疗选择,用于治疗特定的 Tis-T3 声门 LSCC,即使在老年患者中,也因其良好的肿瘤学结果和最小的侵袭性而具有价值。
4 级喉镜,132:135-141,2022 年。